Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (ITOMIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01957514|
Recruitment Status : Terminated (Terminated due to loss of funding.)
First Posted : October 8, 2013
Last Update Posted : September 30, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Stage IV Breast Cancer AJCC v6 and v7 Triple-Negative Breast Carcinoma||Other: Cytology Specimen Collection Procedure Other: Laboratory Biomarker Analysis Other: Quality-of-Life Assessment Other: Questionnaire Administration|
I. To establish the safety and feasibility of collecting, analyzing and storing clinically annotated panomic and other data from serially monitored subjects with metastatic triple negative breast cancer (TNBC) who receive care from up to ten oncology practices across the United States.
I. To determine whether molecular changes associated with resistance to treatment can be identified.
II. To understand subject perceptions regarding panomic data and its application to cancer treatment.
III. To apply other technologies to the characterization of subject tumors as they become available.
Patients undergo collection of tissue biopsy, blood, buccal mucosa, saliva, and urine at baseline. Additional biopsies may be performed prior to treatment change.
After completion of biopsy, patients are followed up at 1 day and 7 days. Patients will be followed indefinitely or for as long as they agree to be in the study, depending on the availability of resources.
|Study Type :||Observational|
|Actual Enrollment :||31 participants|
|Official Title:||Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer|
|Actual Study Start Date :||October 28, 2013|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||June 30, 2018|
Ancillary-Correlative (sample collection)
Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
Other: Cytology Specimen Collection Procedure
Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
Other Name: Cytologic Sampling
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other Name: Quality of Life Assessment
Other: Questionnaire Administration
- Incidence of adverse events resulting from performing multiple biopsies measured by the presence of biopsy-related complications, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 [ Time Frame: Within 1 week of biopsy ]The frequency of adverse events associated with multiple repeated study-related biopsies (or leukapheresis runs) will be determined using simple statistics.
- Infrastructure for acquiring, storing, retrieving and analyzing panomic data from clinical tumor specimens in a clinically relevant timeframe from participating sites [ Time Frame: Up to 2 years ]Findings of potential clinical significance will be included in the reports provided to subjects and oncologists. Similarly, as new information becomes available, information of significance to understanding a subject's tumor or germline genomes may become apparent.
- Change in subject perceptions regarding panomic data and its application to cancer treatment assessed by Intensive Trial of OMics in Cancer baseline and follow up questionnaires [ Time Frame: Baseline to 2 years ]Subject perceptions regarding the value of panomic testing in predicting the optimal treatment for subjects with cancer and for predicting the risk for developing other inherited diseases will be collected.
- Develop process improvements [ Time Frame: Up to 2 years ]The yield of successfully performing various types of analyses from clinically indicated- and study-related biopsies and leukapheresis specimens as well as the time frame necessary for returning reports will be monitored.
- Development and improvement of infrastructure for storing and working with data from subject biopsies [ Time Frame: Up to 2 years ]Data from subjects will be used to test the infrastructure being developing and identify areas that need to be improved.
- Methods required to analyze and integrate data across subjects and with data from the public domain [ Time Frame: Up to 2 years ]Methods and software that can facilitate comparing data from subjects with that deposited in the public domain will be developed.
- Molecular changes associated with treatment response or resistance [ Time Frame: Up to 2 years ]A number of statistical approaches will be used. Will be evaluated by comparing biopsies taken from the same subject pre- and post- anti-cancer treatment, and relating these changes to each subject's outcome.
- Number or frequencies of biopsies or leukapheresis runs [ Time Frame: Up to 2 years ]Safety and feasibility data will be analyzed and the frequency, nature, and severity of adverse events will be summarized.
- Removal of any unnecessary biopsies or generation of redundant data [ Time Frame: Up to 2 years ]Data across biopsies taken from the same individual at the same time point will be compared to assess the need for multiple biopsies.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Subjects have metastatic TNBC
Disease suitable for analysis from either (a) or (b) below:
(a) Research biopsy
- Tumor tissue, which can include bone disease, as determined by physical exam or imaging (as assessed by a trained specialist in radiology)
- Must be collected before the subject receives treatment with a drug they have not received previously
(b) Standard of care biopsy
- Tumor tissue available from a previous biopsy as standard of care (to be determined by the principal investigator [PI] or his designee)
- Must have been collected before subject receives treatment with a drug they have not received previously
- May begin treatment either after enrollment or within several weeks prior to enrollment
- Subjects must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue
- Procedure-specific signed informed consent prior to initiation of any study-related procedures
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky performance status of >= 50%)
- Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP)
- Bevacizumab treatment within 4 weeks prior to biopsy
- Anticoagulation therapy, unless reversed at the time of biopsy
- The enrolling study oncologist has decided that the subject is not fit enough to undergo repeated tissue biopsies
- Presence of a condition or abnormality that in the opinion of the enrolling investigator would compromise the safety of the subject or the quality of the data
- Significant bleeding disorder
- Known brain metastases that have not or will not be treated
- Subjects with a life expectancy of less than 6 months
- Inability to give informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01957514
|United States, Washington|
|Fred Hutch/University of Washington Cancer Consortium|
|Seattle, Washington, United States, 98109|
|Northwest Medical Specialties PLLC|
|Tacoma, Washington, United States, 98405|
|Principal Investigator:||Zhijun Duan||Fred Hutch/University of Washington Cancer Consortium|
|Responsible Party:||University of Washington|
|Other Study ID Numbers:||
NCI-2013-01654 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
8132 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
RG1013004 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
|First Posted:||October 8, 2013 Key Record Dates|
|Last Update Posted:||September 30, 2021|
|Last Verified:||September 2021|
Triple Negative Breast Neoplasms
Neoplasms by Site